Hartman, Axel Haupt, Zvonko Milievi, Tamer Coskun: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
If you have insurance that covers Zepbound or Mounjaro for your indication (most plans do for diabetes
Support for pigmentation regulation
This post is a thorough explanation of the research Adam and his team have done and where we think the commercial value will emerge
While sometimes fruit has been deemed bad for weight loss because of its naturally occurring sugars, a 2016 review found that including fruits (namely whole, fresh fruits) in a balanced diet can support weight loss and healthy weight maintenance
37 XieK.ZhangY.WangY.MengX.WangY.YuY.et al (2020)